Gastroenterology · Hereditary Hemochromatosis
The facts most likely to be tested
Hereditary hemochromatosis is an autosomal recessive disorder caused by a mutation in the HFE gene on chromosome 6, leading to excessive intestinal iron absorption.
The classic clinical triad of bronze skin, diabetes mellitus, and cirrhosis is often referred to as bronze diabetes.
Patients frequently present with arthropathy, most characteristically involving the second and third metacarpophalangeal (MCP) joints.
Initial screening for suspected hemochromatosis requires a fasting transferrin saturation greater than 45% and an elevated serum ferritin level.
The gold standard for confirming the diagnosis and assessing the degree of liver damage is a liver biopsy with Prussian blue staining.
Cardiac manifestations include restrictive cardiomyopathy or dilated cardiomyopathy, which are common causes of morbidity and mortality.
The definitive treatment for hereditary hemochromatosis is therapeutic phlebotomy to reduce total body iron stores.
Vignette unlocked
A 52-year-old male presents to the clinic complaining of progressive fatigue and joint pain in his hands. Physical examination reveals hyperpigmentation of the skin and tenderness at the second and third metacarpophalangeal joints. Laboratory studies demonstrate an elevated fasting transferrin saturation of 65% and a serum ferritin of 1,200 ng/mL. He has a history of type 2 diabetes mellitus and elevated liver enzymes.
What is the most appropriate initial management for this patient?
Therapeutic phlebotomy
The patient presents with the classic triad of bronze skin, diabetes, and arthropathy, confirmed by iron studies; therapeutic phlebotomy is the standard of care to prevent further organ damage.
Full handout
High yield triage
Etiology / Epidemiology
Autosomal recessive disorder of HFE gene mutation; most common in Northern European descent.
Clinical Manifestations
Classic bronze diabetes triad: skin hyperpigmentation, diabetes mellitus, and cirrhosis.
Diagnosis
Gold standard is liver biopsy; screening via serum ferritin > 1000 ng/mL and transferrin saturation > 45%.
Treatment
First-line is therapeutic phlebotomy; avoid iron supplements and vitamin C.
Prognosis
Risk of hepatocellular carcinoma remains even after iron depletion; monitor with AFP.
Full handout
Epidemiology & Etiology
Primary hereditary hemochromatosis is an autosomal recessive disorder caused by mutations in the HFE gene (C282Y). It is the most common genetic disorder in individuals of Northern European ancestry. Onset typically occurs between ages 40-60, with males presenting earlier due to lack of menstrual iron loss.
Pertinent Anatomy
Excess iron deposits primarily in the liver (hepatomegaly/cirrhosis), pancreas (islet cell destruction), heart (restrictive cardiomyopathy), and joints (arthropathy).
Pathophysiology
The HFE mutation leads to decreased hepcidin production, the master regulator of iron homeostasis. This results in unregulated intestinal iron absorption and subsequent systemic iron overload. Iron deposition causes oxidative stress via Fenton reaction, leading to organ fibrosis and tissue damage.
Clinical Manifestations
Patients often present with bronze diabetes, characterized by skin hyperpigmentation and diabetes mellitus. Other findings include arthropathy (classically 2nd/3rd MCP joints), hypogonadism, and restrictive cardiomyopathy. Watch for signs of decompensated cirrhosis including ascites and variceal bleeding.
Diagnosis
Initial screening includes transferrin saturation > 45% and serum ferritin > 1000 ng/mL. The gold standard for confirming iron overload and degree of fibrosis is liver biopsy. Genetic testing for HFE mutation is diagnostic in symptomatic patients.
Treatment
The first-line treatment is therapeutic phlebotomy to reduce iron stores to target ferritin levels of 50-100 ng/mL. Avoid iron supplements, vitamin C, and alcohol to prevent further liver injury. Chelation therapy with deferoxamine is reserved for patients who cannot tolerate phlebotomy.
Prognosis
Early treatment prevents progression to cirrhosis and diabetes. Patients with established cirrhosis remain at high risk for hepatocellular carcinoma and require regular screening with AFP and abdominal imaging.
Differential Diagnosis
Alcoholic liver disease: AST:ALT ratio > 2:1
Wilson disease: low ceruloplasmin and Kayser-Fleischer rings
Chronic Hepatitis C: positive HCV antibodies/RNA
Porphyria cutanea tarda: blistering skin lesions on sun-exposed areas
Secondary iron overload: history of chronic blood transfusions